Benlysta's Broad Label Prepares The Way For A New Blockbuster
Executive Summary
The broad labeling that FDA approved for Benlysta (belimumab), the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.